TranS1 Inc. (TSON) has announced that it expects revenues to be approximately $6.8 million to $6.9 million in the third quarter of 2009 compared to $6 million reported in the year-ago quarter. Results for the quarter are expected to be released on Oct 29, 2009.  While revenues are expected to increase from the year-ago period, they are still predicted to be lower than the previous guidance of $7.4 million to $7.9 million. The lower guidance is primarily based on weak sales of the company’s AxiaLIF lumbar fusion device due to insurance reimbursement concerns.  However, management considers these low revenues as a short-term event and is confident about long-term growth primarily due to the expanding minimally invasive spine surgery market.  TranS1 is working on educating existing and potential customers about the utilities of the AxiaLIF lumbar fusion device to increase its sales. The device allows surgeons ...